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Background: Approximately 10%–20% of kidney transplant (KT) recipients suffer from 
acute rejection (AR); thus, sensitive and accurate monitoring of allograft status is recom-
mended. We evaluated the clinical utility of donor-derived DNA (dd-DNA) detection in the 
urine of KT recipients as a non-invasive means for diagnosing AR. 
Methods: Urine samples serially collected from 39 KT recipients were tested for 39 single-
nucleotide variant loci selected according to technical criteria (i.e., high minor allele fre-
quency and low analytical error) using next-generation sequencing. The fraction of dd-DNA 
was calculated and normalized by the urine creatinine (UCr) level (%dd-DNA/UCr). The di-
agnostic performance of %dd-DNA/UCr for AR was assessed by ROC curve analysis.
Results: There was an increasing trend of %dd-DNA/UCr in the AR group before subse-
quent graft injury, which occurred before (median of 52 days) histological rejection. The 
serum creatinine (SCr) level differed significantly between the AR and non-AR groups at 
two and four months of follow-up, whereas %dd-DNA/UCr differed between the groups at 
six months of follow-up. The combination of %dd-DNA/UCr, SCr, and spot urine protein 
(UPtn)/UCr showed high discriminating power, with an area under the ROC curve of 0.93 
(95% confidence interval: 0.81–1.00) and a high negative predictive value of 100.0%.
Conclusions: Although the dd-DNA–based test cannot eliminate the need for biopsy, the 
high negative predictive value of this marker could increase the prebiopsy probability of 
detecting treatable injury to make biopsy an even more effective diagnostic tool.
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INTRODUCTION
Kidney transplantation (KT) is the preferred treatment for pa-
tients with end-stage renal disease (ESRD). Although KT is a 
life-saving treatment, transplant recipients require lifelong follow-
up, with intensive surveillance of allograft function. Approxi-
mately 10% and 20% of KT recipients suffer from acute rejec-
tion (AR), which is a major risk factor of graft failure [1].
Diagnostic biopsies are performed in cases with a strong clini-
cal suspicion of AR, which mainly depends on the deterioration 
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of graft function determined as the estimated glomerular filtra-
tion rate (eGFR) measured in terms of serum creatinine (SCr) 
levels [2]. However, the level and rate of SCr change poorly pre-
dict graft failure, since the deterioration of kidney function fol-
lows graft injury [3]. Moreover, alterations in SCr levels are not 
specific, as they may also indicate an intrinsic process such as 
renal artery stenosis, recurrence of original disease, a transient 
process, or AR [4]. However, the current strategies for monitor-
ing graft dysfunction are not sufficient for indicating the need for 
biopsy since up to 10.8% of grafts have normal histological re-
sults [5]. Therefore, a novel strategy is needed to decide whether 
to perform diagnostic biopsy in a timely manner.
Surrogate markers such as transcriptomic molecular profiles 
related to graft injury have been evaluated for the diagnosis of 
AR [6–9]. Although these markers can provide rich biological 
information, the degradative nature of RNA is a major barrier to 
their widespread adoption for clinical diagnosis [10]. In addition, 
these markers cannot accurately discriminate between various 
origins of damage, since they can be released from a remnant 
kidney or can be due to kidney-intrinsic etiologies [11]. 
Donor-derived DNAs (dd-DNAs) exist as extracellular cell-free 
DNA (dd-cfDNA) in the recipient or as an intracellular compo-
nent of a donor cell (cellular dd-DNA), and both forms are likely 
to be released from necrotic or apoptotic cells in a transplanted 
organ [12, 13]. As the levels of dd-DNAs increase when an al-
lograft is damaged by rejection or viral infection, they can be 
used as markers for graft injury [14, 15]. To distinguish dd-DNA 
from recipient DNA, detection of autosomal single-nucleotide 
variants (SNVs), given their wide range of uses, increases the 
discriminating power of dd-DNAs [13, 16].
Since graft cells or DNA can gain access to the urinary space, 
urine represents an appropriate sample type to investigate intra-
graft events [17]. Therefore, the urine of KT recipients may 
serve as a form of liquid biopsy, offering a truly non-invasive di-
agnostic method. Along with urinary tubule protein marker lev-
els, the urinary dd-DNA level may increase  after graft injury 
[18]. 
In this study, we evaluated the utility of urinary dd-DNA com-
bined with other laboratory parameters to guide the timeliness 
of diagnostic biopsy. We evaluated clinical characteristics asso-
ciated with outcomes and serially increasing levels of urinary 
dd-DNAs by multiplexing 39 autosomal informative SNVs identi-
fied through next-generation sequencing (NGS), and compared 
the time of urinary dd-DNA to increase with the time point of 
histological AR.  
MATERIALS AND METHODS
Study population and samples
Forty-three patients with ESRD who had undergone scheduled 
KT from related or unrelated living donors from December 2014 
to June 2015 at Severance Hospital, Seoul, Korea, were in-
cluded in this observational prospective (sample collection and 
tests were performed the day before KT) and retrospective (clin-
ical data were collected from medical records) study. Sample 
size was calculated based on the formula described by Buderer 
[19], with a maximum clinically acceptable two-tailed 95% con-
fidence interval (CI) width of 0.1, estimated disease prevalence 
of 0.2, expected sensitivity of 0.9, and expected specificity of 
0.9. Blood samples (>3 mL) were collected before KT to assess 
informative SNVs, whereas post-KT urine (>10 mL) and blood 
samples (>3 mL) were prospectively collected at the time of se-
rial follow-up visits at 1 week; 2 weeks; and 1, 2, 4, and 6 
months, as regular intervals; and at the time of biopsy. However, 
collection was discontinued at the time of AR detection (Fig. 1).
Patients’ demographic and clinical data were extracted by ret-
rospectively reviewing electronic medical records. AR was diag-
nosed by graft biopsy, which was performed for patients with 
deteriorating graft function. Histological diagnosis of AR was 
made by a single pathologist according to the Banff 2007 crite-
ria [20]. The Institutional Review Board (IRB) of Severance Hos-
pital approved this study (IRB 2015-1707-001). Written in-
formed consent was obtained from all patients in accordance 
with the Declaration of Helsinki.
Sample collection and processing
First morning concentrated midstream urine samples (10–15 
mL) were collected in sterile containers. Within 2 hours of col-
lection, the samples were centrifuged at 2,000×g for 20 min-
utes at room temperature (20–25°C). To acquire urinary cellular 
dd-DNA and to avoid its degradation, the supernatant was sep-
arated from the urine pellet containing cells and cell debris. The 
cell pellet was transferred to a 1.5-mL microcentrifuge tube 
containing 1 mL of TRIzol (Invitrogen, Carlsbad, CA, USA) and 
stored at −80°C for further analysis. SCr, spot urine protein 
(UPtn), and urine creatinine (UCr) levels were measured using 
a Beckman Coulter AU680 analyzer (Beckman Coulter, Fuller-
ton, CA, USA).
DNA extraction and multiplex PCR targeted amplicon 
sequencing
Genomic DNA was extracted from urinary cell pellets using QIA-
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amp MinElute Column kit (Qiagen, Hilden, Germany) according 
to the standard procedure. For library construction, the optimal 
input DNA was 20 ng according to the manufacturer’s protocol; 
samples of two recipients with a urinary DNA level <10 ng/μL 
or failed amplification (PCR-failed samples), and samples of two 
recipients with urinary tract infections (UTIs) were excluded.
Thirty-nine SNVs were selected according to the following cri-
teria: minor allele frequency (MAF) >0.4, known low polymerase 
error, high coverage (>1,000 counts) in the dbSNP database 
(http://www.ncbi.nlm.nih.gov/SNP), low linkage (>500-kb apart), 
no more than one additional SNV with MAF >0.1 in the ampli-
con, and no known association with disease. In addition, targets 
of interest were selected if the adjacent allele was less than 5-bp 
away with a MAF of >0.5 to visually detect the sequencing bias.
Amplicons were indexed with dual-matched adapters (i5 and 
i7) with Unique Molecular Indices (UMI) designed to signifi-
cantly reduce index misassignment. All 39 libraries were se-
quenced on a NextSeq550 flowcell (Illumina, San Diego, CA, 
USA) using a V3 NextSeq550 sequencing kit (Illumina). Further 
data analysis, including quality check, sequence alignment, and 
variant calling, were performed with a customized bioinformat-
ics pipeline.
Analytical performance of SNV markers
The limit of detection (LoD) for dd-DNA measurement was esti-
mated by serially diluting equimolar amounts of DNA extracted 
from the whole blood of two unrelated individuals (normal con-
trols) using dilution factors of 50%, 10%, 1%, 0.1%, 0.01%, 
0.001%, and 0.0001%. The dilution factors were transformed 
to log base 10 to warrant low-level values. The estimation was 
performed using fragmented DNA at a total input mass of 20 
ng. We used the linear regression model to fit the data to the re-
gression line and G-test to determine the appropriateness of the 
model [21]. 
Fig. 1. Flow diagram of this study. A total of 39 recipients were evaluated for %dd-DNA/UCr. Two of four recipients with inadequate PCR 
results and two other recipients with bacterial UTIs were excluded.
Abbreviations: dd-DNA, donor-derived DNA; UCr, urine creatinine; UTIs, urinary tract infections; SNV, single-nucleotide polymorphism; ABMR, antibody-
mediated rejection; TCMR, T cell-mediated rejection; FGS, focal glomerulosclerosis; CMV, cytomegalovirus. 
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Table 1. Informative SNVs and variant allele frequency distributions 
of 39 recipients according to days post-transplantation
Recipient 














KT01 11 Non-AR 28 0.315 8,156
105 0.262 13,898
168 1.476 10,231
KT02 7 Non-AR 168 0.885 11,317
196 6.545 9,866
KT03 11 AR 14 2.008 7,338
21 15.189 234
35 1.798 12,158





KT05 10 AR 14 18.449 687
28 60.199 859
98 41.693 1,059
KT06 6 Non-AR 21 0.15 1,170
84 0.22 1,181
224 27.358 379








KT09 12 Non-AR 7 22.247 200
14 3.045 9,065




KT11 7 Non-AR 56 15.27 198
168 53.733 197
196 66.709 570




(Continued to the next)
Recipient 














KT13 3 Non-AR 21 7.485 2,917
98 1.096 12,332
140 6.866 6,218












KT16 5 AR 7 47.212 4,863
14 30.175 11,197
28 38.849 326


























(Continued to the next)
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Recipient 














KT22 10 AR 7 37.995 595
28 2.386 7,236
35 5.667 1,772





KT24 12 Non-AR 7 0.779 7,900
14 20.215 212

























KT29 16 Non-AR 7 81.141 1,448
14 87.269 156
KT30 19 Non-AR 7 59.978 215
21 83.587 607
KT31 10 Non-AR 7 3.449 15,343
14 3.683 2,645
Table 1. Continued
(Continued to the next)
Recipient 














KT32 12 Non-AR 7 1.42 4,315
14 9.069 314
KT33 11 AR 7 22.03 7,999
21 5.062 19,788
56 4.564 20,496








KT36 14 Non-AR 14 27.191 814
28 14.659 1,620
56 18.461 201




KT38 10 Non-AR 7 45.796 156
28 14.405 159
KT39 10 AR 14 2.542 7,328
28 49.321 402
35 4.727 499
*The following 39 SNV markers were used for the chimerism calculation: 
rs3738561, rs6480497, rs4757113, rs7983800, rs3745331, rs10426644, 
rs2540307, rs1358833, rs62270249, rs1436501, rs9386037, rs2159478, 
rs11023112, rs6589967, rs8022985, rs1202017, rs645107, rs6921313, 
rs4072990, rs6676162, rs72735619, rs11187560, rs10832201, 
rs7950719, rs6590643, rs1731550, rs10777988, rs4496026, rs12327492, 
rs1348784, rs281544, rs6445350, rs3819864, rs6863833, rs1423013, 
rs1561681, rs73230060, rs6995506, and rs16904057.
Abbreviations: SNV, single-nucleotide variant; VAF, variant allele frequency; 
AR, acute rejection, including acute antibody-mediated rejection and T cell-
mediated rejection.
Table 1. Continued
Linear regression analysis indicated a good linear correlation 
(R2 =0.89, P =0.001), and the LoD was validated from 0.01% 
of the NGS results (% NGS=1.38×% theoretical dilution−0.33). 
The mean number of informative SNVs per patient was 10.4, 
with actual numbers ranging from 3 to 19. The average sequenc-
ing depth per sample was 4,199.5±4,749.8 reads. The infor-
mative markers were distributed across 18 chromosomes, with 
a mean product size of 83.6±6.2 bp and a mean distance be-
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Table 2. Demographic data of the 39 donors and recipients
Characteristics* AR group (N=9) Non-AR group (N=30) P†
Age at transplantation (yr)
Recipient 49.0 (44.0–53.0) 44.0 (36.0–54.0) 0.385
Donor 47.0 (45.0–53.0) 40.0 (33.0–49.0) 0.054
Sex
Female/Male 2/7 (28.6%) 9/21 (42.9%) 0.595
Body mass index (kg/m2)
Recipient 22.4 (20.6–24.2) 22.5 (18.7–25.9) 0.958
Donor 22.3 (21.0–23.5) 22.5 (20.4–24.7) 0.741
Allograft length (cm) 10.5 (10.3–11.4) 11.0 (10.3–11.3) 0.446
Donor type (living)
Genetically related 2/9 (22.2%) 22/30 (73.3%) 0.001
Parent 0 12
Sibling 2 10
Genetically unrelated (Spouse) 7/9 (77.8%) 8/30 (26.7%)
Tacrolimus trough level (ng/mL) 3.60 (3.10–4.85) 4.73 (3.8–5.82) 0.110
ABO incompatibilities, N (%) (donor→recipient) 1 (11.1%) 10 (33.3%) 0.421
HLA mismatch (HLA-A, B, DR) 5 (3–6) 3 (2–4) 0.044
PRA Screening (%) (average) 0.0 (0.0–0.0) 0.0 (0.0–0.75) 0.208
*All data are shown as median (IQR) unless otherwise indicated (i.e., N, %); †Significant P values are in bold.
Abbreviations: AR, acute rejection, including acute antibody-mediated rejection and T cell- mediated rejection; PRA, panel-reactive antibody; SD, standard 
deviation.
tween markers on the same chromosome of 99.8±67.9 Mb 
(Table 1).
Measurement of dd-DNA
The fraction of dd-DNA (%dd-DNA) was calculated by dividing 
the read numbers of variant sequences corresponding to a do-
nor genotype by the total coverage numbers of target sequences 
in each informative SNV. Averaging percentages were calculated 
for all informative SNVs. If a donor-specific genotype was het-
erozygous, recipient-specific variant read numbers were multi-
plied by two based on the method described in our previous 
study [22]. Background levels of an alternate allele resulting 
from an amplification or sequencing error were subtracted from 
the alternate allele frequency for each SNV site. The calculated 
%dd-DNA was normalized against the UCr level of a sample. 
The maximal %dd-DNA/UCr was defined as the highest %dd-
DNA/UCr level among serial %dd-DNA/UCr values measured 
for each recipient (in both the AR and non-AR groups) at a cer-
tain time point and as indicative of the occurrence of severe 
molecular injury.
Statistical analysis
Continuous variables with non-normal distribution, including the 
age and body mass index (BMI) of the recipient and donor, al-
lograft length, number of mismatched HLA types, and average 
percentage of screened panel-reactive antibody (PRA), are pre-
sented as median (interquartile range [IQR]). Continuous values 
such as %dd-DNA/UCr and SCr levels between the two groups 
(AR and non-AR) were compared based on the Mann-Whitney 
rank-sum test and are presented as median (range). Categorical 
variables, including the sex of recipient and donor, relation be-
tween the recipient and donor, and ABO compatibility, are pre-
sented as numbers and percentages. These variables were 
compared using either the chi-square test or Fisher’s exact test, 
as appropriate. The diagnostic performance of %dd-DNA/UCr 
(maximal %dd-DNA/UCr) was evaluated by receiver operating 
characteristic (ROC) curve analysis, and the glm function for 
modeling and visualization of plots was used in the R software, 
version 3.5.2, 64-bit (R Foundation for Statistical Computing, 
Vienna, Austria). The sensitivity and specificity in the ROC curve 
analysis were estimated using the Youden index. P <0.05 was 
considered statistically significant.
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Histological diagnosis (Banff 2007)
Time to rejection 
(days)
KT03 F 28 Spouse ABMR, grade II and TCMR, type IB (g0, t3, i3, v0, cg0, ct0, ci0, cv0, mm0, ah0, ptc2) 33
KT05 M 56 Spouse Suspicious for TCMR (g0 t1 i1 v0 cg0 ct0 ci0 cv0 ah0 mm0 ptc0) 113
KT07 M 49 Spouse TCMR, type IB (g0 t3 i3 v0 cg0 ct0 ci0 cv0 ah0 mm0 ptc2) 110
KT08 M 61 Spouse Suggestive of ABMR (g0 t1 i1 v0 cg0 ct0 ci0 cv0 ah1 mm0 ptc0) 163
KT16 M 49 Sibling ABMR (g3 t0 i3 v2 cg0 ct0 ci0 cv0 ah0 mm0 ptc2) 46
KT22 F 40 Sibling ABMR, grade II (g3 t0 i0 v0 cg0 ct0 ci0 cv0 ah0 mm0 ptc1) 70
KT33 M 53 Spouse TCMR, type IIA (g0 t2 i2 v1 cg0 ct0 ci0 cv0 mm0 ah0 ptc0) 63
KT37 M 46 Spouse ABMR, type II (g0 t1 i2 v0 cg0 ct0 ci0 cv0 mm0 ah0 ptc3) 56
KT39 M 44 Spouse TCMR, type IIA (g1 t3 i3 v2 cg0 ct0 ci0 cv0 mm0 ah0 ptc2) 49
Abbreviations: KT, kidney transplantation; AR, acute rejection; ABMR, antibody-mediated rejection; TCMR, T-cell mediated rejection.
RESULTS
Patient characteristics and %dd-DNA/UCr
AR was more likely to occur in recipients who had received a 
transplant from an unrelated donor (P =0.001) and had a 
greater number of mismatched HLA types (P =0.044). There 
were no significant differences between the AR and non-AR 
groups in the age at KT (recipient and donor), sex of the recipi-
ent, BMI (recipient and donor), allograft length, tacrolimus 
trough level, ABO incompatibility, and average % PRA (Table 2).
AR diagnosis and %dd-DNA/UCr
AR was diagnosed in nine recipients. Five recipients had acute 
antibody-mediated rejection and four had acute T-cell mediated 
rejection (Table 3). AR occurred at a median of 63 (47.5–111.5) 
days after the KT. Eight of the nine recipients developed rejec-
tion in the first four months after KT.
There was wide intra-recipient variation of %dd-DNA/UCr in 
the urine, even when considering all 56 samples of the 20 re-
cipients in the non-AR group whose allograft remained stable 
(dd-DNA/UCr range: 0.10%–48.92%), suggesting that there 
might be a response to other subclinical acute graft injuries. 
However, there was an increasing trend of %dd-DNA/UCr in the 
AR group before subsequent graft injury. The elevation of %dd-
DNA/UCr occurred from 85 days to 12 days earlier (median of 
52 days) than histological rejection.
The SCr differed significantly between the AR and non-AR 
groups at 2 and 4 months (P <0.05), whereas %dd-DNA/UCr 
differed significantly at 6 months of the follow-up period (Fig. 2)
Fig. 2. Comparison of SCr and %dd-DNA)/UCr between groups (AR vs. Non-AR). (A) SCr and (B) %dd-DNA)/UCr between the AR and 
non-AR groups at different time points (at 2 weeks 2, months 1, 2, 4, and 6) after transplantation. P values are presented above the box 
plots. Median (interquartile range [IQR]) values are presented at the bottom of graphs, outside of the box plots.













MEDIAN 17.68 15.24 33.05 7.85 41.40 14.41 19.67 11.67 59.00 13.13
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Table 4. Comparison of AUC values of ROC curves for % maximal dd-DNA/UCr, SCr, UPtn/UCr, and their combinations





%dd-DNA/UCr† 0.58 (0.42–0.75) 47.50% 53.6 77.8 15.2 95.7
SCr (mg/dL) 0.79 (0.60–0.98) 1.3 78.3 83.3 0.58 96.6
UPtn/UCr 0.78 (0.57–0.98) 58.4 57.9 100.0 33.3 100.0
SCr and UPtn/UCr 0.91 (0.76–1.00) 0.2 86.7 100.0 60.0 97.7
%dd-DNA/UCr, SCr and UPtn/UCr 0.93 (0.81–1.00) 0.2 86.7 100.0 60.0 100.0
*The cut-off values for %dd-DNA/UCr, SCr, and UPtn/UCr were individually selected to yield the highest Youden index, whereas the cut-offs for their combi-
nations were determined using a non-parametric general linear model. †The diagnostic performance of %dd-DNA/UCr, evaluated by ROC curve analysis, 
were values of maximal %dd-DNA/UCr, which is defined as the highest %dd-DNA/UCr level among serial %dd-DNA/UCr values measured for each recipient 
(in both the AR and non-AR groups) at a certain time point.
Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic; CI, confidence interval; dd-DNA, donor-derived DNA; UCr, urine creati-
nine; SCr, serum creatinine; UPtn, spot urine protein.
Diagnostic performance of dd-DNA for AR
The area under the ROC curve (AUC) for discriminating AR 
from non-AR groups was poor for %dd-DNA/UCr alone, which 
cannot be used to establish the diagnosis of AR. The AUC of 
SCr alone and UPtn/UCr alone were higher than that of %dd-
DNA/UCr alone. The discriminating power improved with the 
combination of %dd-DNA/UCr, SCr, and UPtn/UCr (0.93), 
which was similar to that observed with the combination of SCr 
and UPtn/UCr (0.91). 
The positive predictive value (PPV) of %dd-DNA/UCr alone 
compared to SCr alone showed improved performance (15.2% 
vs. 0.58%) when screening AR; however, the performance was 
still inferior to that of UPtn/UCr (33.3%). The PPV of %dd-DNA/
UCr alone improved with the combination of SCr and UPtn/UCr 
to 60.0%. However, a high negative predictive value (NPV) was 
found for %dd-DNA/UCr, SCr, and Uptn/UCr, both individually 
and in combination (Table 4).
DISCUSSION
In this study, the clinical performance of %dd-DNA/UCr for AR 
diagnosis was assessed and compared with the performance of 
standard diagnostic tools such as allograft biopsy and traditional 
analyses of laboratory parameters, including SCr and UPtn. We 
applied 39 highly discriminative autosomal SNVs with analytic 
accuracy. We suggest autosomal SNVs as the most appropriate 
markers of allograft rejection in clinical practice because analy-
sis of the Y chromosome is only suitable for female KT recipi-
ents from male donors, and more than half of KT in Korea are 
from genetically related donors [23, 24].
Several studies have employed methods that quantify dd-
DNA, including quantitative PCR, digital-droplet PCR (dPCR), 
and targeted NGS [16]. dPCR is a sensitive and cost-effective 
method to quantify circulating nucleic acids; however, depend-
ing on the instrument, it is susceptible to poor test design, lead-
ing to cross-reactivity and false positives [25]. NGS also has the 
potential to introduce biases such as pre-amplification of dd-
DNA [26]. Thus, we selected targets of interest with a GC con-
tent <61% and adjacent alleles within a 5-bp region having an 
MAF of >0.5 to visually detect any sequencing bias. Since 
NGS-based multiplex platforms are feasible for hundreds of 
primer pairs and their cost is continuously reducing, their wide-
spread utility is expected, especially for the monitoring of multi-
ple organ transplantations from different donors.
Numerous types of nucleic acids can be measured in the 
urine, including cfDNA, cellular DNA, and RNAs such as mi-
croRNAs, long non-coding RNAs, and mRNAs. The fraction of 
cellular DNA in the urine is far greater than that of cfDNA, 
which occurs in donor-derived vascular/tubular cells and lym-
phocytes in the urine of KT recipients [18, 27]. Many clinical 
studies have evaluated the diagnostic value of dd-DNA, espe-
cially in the form of plasma and urinary cell-free dd-DNA (dd-
cfDNA), for the prediction of AR [14, 15, 28–30]. The levels of 
dd-cfDNA were shown to be sensitive to graft injury, with unsta-
ble kinetics in the early post-transplantation phase [31]. This 
means that their fluctuations need to be interpreted in conjunc-
tion with other clinical and laboratory parameters [16]. More-
over, the low level of cfDNA is problematic, as many molecular 
techniques require higher DNA amounts, and contamination by 
cellular DNA or PCR inhibitors affects NGS performance [32]. 
Therefore, we concluded that cellular dd-DNA is more suitable 
for multiplex PCR enrichment for urine samples of KT recipi-
ents, and the abundant cellular dd-DNA is more adequate to 
conduct monitoring.
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We excluded patients with UTI to minimize confounding fac-
tors. High intra-recipient variation, with dd-DNA/UCr ranging 
from 0.10% to 48.92%, was observed in non-AR recipients. 
This result was not surprising because cellular dd-DNA reflects 
tissue breakdown due to injury in a donor organ, and regenera-
tion of a transplanted kidney is a normal physiological process 
after transplantation [33, 34]. However, the observed %dd-
DNA/UCr fluctuation could not be histologically explained, since 
a protocol biopsy was not obtained at each time point.
Increased %dd-DNA/UCr before AR was observed and was 
significantly discriminable from that in the non-AR group at 
6-month follow-up, whereas a difference in SCr levels was ob-
served between the AR and non-AR groups at the 2-month and 
4-month follow-ups. The inclusion of %dd-DNA/UCr with SCr 
and UPtn/UCr did not affect the diagnostic performance , which 
may be due to relatively scant number of urine samples avail-
able for %dd-DNA/UCr measurements owing to the unpredict-
able timing of AR and biological variation among urine samples. 
However, molecular injury, represented as the maximal %dd-
DNA/UCr, occurred earlier than clinical or histological AR, with 
a median of 52 days, which implies that %dd-DNA/UCr is a 
sensitive marker for AR.
This study has several limitations. First, we did not perform a 
protocol biopsy for surveillance and the total number of biopsy-
confirmed AR allografts was small. Therefore, we could not esti-
mate the baseline %dd-DNA/UCr for all biopsy-confirmed stable 
allografts. Second, only living-donor KT recipients were included 
in the study since part of the samples and consent had to be 
obtained before KT. Since the majority of transplantations use 
organs derived from deceased donors, the translation of our re-
sults to the deceased donor pool remains to be confirmed.
To the best of our knowledge, this is the first study to examine 
cellular dd-DNA from the urine samples of KT recipients using 
an SNV-based NGS approach and to evaluate the diagnostic 
performance of this approach with adjunctive biomarkers. Our 
results might help patients identify a possibility of transplant re-
jection before deciding on proceeding with a kidney biopsy. In-
formed biopsy decisions are needed to reduce morbidity and 
increase the cost-effectiveness of transplant recipient surveil-
lance. Our strategy would be especially useful for patients who 
are on anticoagulation therapy or have other reasons to avoid 
biopsy. Based on our research, additional studies regarding an-
alytical standardization and validation of urinary dd-DNA are 
needed for its clinical application.
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